Scarica l'app Stockscreener
14.64
1.41%
-0.21
Dopo l'orario di chiusura:
14.85
0.21
+1.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Biohaven Ltd Borsa (BHVN) Ultime notizie
Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP - MarketBeat
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)? - Sahm
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands - simplywall.st
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - Yahoo Finance
Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven - Stock Titan
Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN - MarketBeat
Biohaven (BHVN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven 2Q Loss/Shr 91c >BHVN - Moomoo
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biohaven Pharma stock price target raised to $23 by RBC Capital - Investing.com Nigeria
Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says - Moomoo
Biohaven Ltd. (BHVN) Stock Analysis: Exploring The 57.73% Potential Upside For Investors - DirectorsTalk Interviews
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Australia
Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Biohaven narrows Q2 losses 29%, initiates pivotal Graves' trial - scanx.trade
Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending - Kalkine Media
Biohaven reports Q2 2026 net loss of $137.3M, cash and marketable securities $267.9M - TradingView
Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity - Stock Titan
Biohaven Ltd. reports results for the quarter ended June 30Earnings Summary - TradingView
Biohaven Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Biohaven earnings set to show cash burn ahead of epilepsy data - Investing.com UK
Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Understanding Momentum Shifts in (BHVN) - Stock Traders Daily
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Biohaven (BHVN) Institutional Ownership 2026 - MarketBeat
Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide? - simplywall.st
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors - Morningstar
Biohaven Adds Technology Investor John Yetimoglu to Board as AI Strategy Advances - citybiz
Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026 - marketscreener.com
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 71.53% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven (BHVN) Expected to Release Quarterly Earnings on Monday - MarketBeat
Biohaven Ltd. $BHVN Shares Bought by Janus Henderson Group PLC - MarketBeat
Stempoint Capital LP Takes $13.49 Million Position in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 58% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy - simplywall.st
Federal jury awards Yale University, Biohaven $4M in trade secret suit - Westfair Communications
Yale, Biohaven Win $4M In Biotech Trade Secret Trial - Law360
Why is Biohaven Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada
Yale, Biohaven Win $4 Million Verdict Over Drug-Development Tech - Bloomberg Law News
Federal jury awards Yale, Biohaven $4M in lawsuit over trade secrets - Hartford Business Journal
Biohaven and Yale win $4M verdict in trade secret case - Investing.com Nigeria
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million - TradingView
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biohaven Ltd (BHVN) Institutional Confidence - TradingKey
Biohaven Ltd (BHVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biohaven Ltd (BHVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BHVN|Biohaven Ltd|Price:14.320|Chg%:-0.320 - TradingKey
BHVN|Biohaven Ltd|Price:14.563|Chg%:+0.243 - TradingKey
Biohaven Ltd (BHVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Biohaven Ltd. Revenue Breakdown – NYSE:BHVN - TradingView
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 53% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven Pharmaceutical Holding Company Ltd (BHVN) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload - Finansavisen
How Biohaven’s (BHVN) R&D Leadership Shuffle Will Impact Investors - simplywall.st
Biohaven Ltd. (NYSE: BHVN) legal chief discloses holdings - Stock Titan
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):